Af­fimed cuts up to 50% of em­ploy­ees to sup­port clin­i­cal projects, CEO de­parts

Last year
People
R&D

J&J makes $2B push in­to AD­Cs with Am­brx buy­out in on­col­o­gy deal spree: #JPM24

Last year
Deals
Pharma

Mer­ck brings Har­poon Ther­a­peu­tics and its PhI/II T cell en­gager in­to the fold for $680M

Last year
Deals

No­var­tis li­cens­es two car­dio­vas­cu­lar RNAi drugs from Chi­nese biotech for $185M up­front

Last year
Deals
R&D

New David Liu study de­tails virus-like de­liv­ery sys­tem for prime edit­ing

Last year
Discovery
Cell/Gene Tx

No­var­tis strikes $250M buy­out for Mer­ck Serono spin­out's au­toim­mune 'pipeline-in-a-drug'

Last year
Deals

Ver­tex paus­es di­a­betes islet cell ther­a­py study af­ter two pa­tient deaths it says are un­re­lat­ed to drug

Last year
R&D
Cell/Gene Tx

Ex­clu­sive: Al­pha­bet's Iso­mor­phic inks first phar­ma deals with Eli Lil­ly and No­var­tis for $83M up­front, $2.9B in ...

Last year
Startups
Deals

Cerev­el failed to draw Pfiz­er in­to a bid­ding war, but got Ab­b­Vie to up its price any­way, fil­ing shows

Last year
Deals

Roche leads pre-JPM deal spree; Roger Perl­mut­ter’s new phar­ma force; In­side Sage’s big tri­umph and fail­ure; Late ...

Last year
Weekly

Gene edit­ing com­pa­ny Metageno­mi sub­mits IPO pa­per­work in third planned biotech list­ing of 2024

Last year
Financing
Startups

Ar­riVent files for IPO, rais­ing funds as it takes PhI­II can­cer drug through tri­al

Last year
Financing
Startups

Drug pric­ing ex­perts skep­ti­cal that Flori­da's drug im­port plan will work

Last year
Pharma

Califf and Marks call for clin­i­cians to help ad­dress 'large vol­ume' of vac­cine mis­in­for­ma­tion

Last year
FDA+

Ex­clu­sive: Il­lu­mi­na board mem­bers al­lege ac­tivist di­rec­tor gave con­fi­den­tial in­for­ma­tion to Ic­ahn for use in law­suit

Last year
Diagnostics
Law

GSK’s Vi­iV spon­sors new sea­son of Ru­Paul TV show to spark HIV pre­ven­tion con­ver­sa­tions

Last year
Pharma
Marketing

Semaglu­tide as­so­ci­at­ed with low­er risk of sui­ci­dal ideations com­pared to non-GLP-1 drugs: NIH-fund­ed study

Last year
Pharma

Fu­sion Phar­ma marks in-house ra­dio­phar­ma man­u­fac­tur­ing suc­cess, de­tails PhII/III tri­al study

Last year
Manufacturing

'If you could have the next Prozac, that’s in­tox­i­cat­ing': Sage’s post­par­tum de­pres­sion tri­umph and the fail­ure ...

Last year
R&D
Pharma

No­var­tis adds In­di­anapo­lis site to its man­u­fac­tur­ing ca­pac­i­ty for ra­di­oli­gand drug Plu­vic­to

Last year
Pharma
Manufacturing

Mer­ck CEO in­di­cates in­ter­est in GLP-1 com­bi­na­tion ther­a­pies, may pur­sue deals

Last year
Deals
R&D

IQVIA and Pro­pel aban­don merg­er af­ter FTC probe and in­junc­tion

Last year
Pharma
Marketing

Boehringer’s deal spree; Prax­is’ li­cens­ing pact with Shang­hai biotech; Vi­co Ther­a­peu­tics rais­es $60M

Last year
News Briefing

Psy­che­del­ic-as­sist­ed drug de­vel­op­er MAPS PBC nabs $100M, re­names to Lykos Ther­a­peu­tics

Last year
Financing
Startups
First page Previous page 221222223224225226227 Next page Last page
A service from the Financial Times